ROCKVILLE, MD and SHENZHEN, CHINA, Jan 5, 2023 – (ACN Newswire) – HighTide Therapeutics Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the closing of a $107 million Series C/C+ financing led by the TCM Healthcare Fund of Guangdong…
Read More
About The Author
